Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For

Efficacy, Safety Data Pooled, Limited

 
• By Mandy Jackson
  
Analysts and investors need more data to measure MariTide's competitiveness (Shutterstock)

More from Clinical Trials

More from Therapy Areas